Journal Articles Su, W., Gangji, A., Margetts, P., Clase, C., Ganame, J., Noseworthy, M., Bosch, J., Lonn, E., Yusuf, S., Jain, A. & Brimble, S. (2011). The FLUID study protocol: a randomized controlled study on the effects of bioimpedance analysis and vitamin D on left ventricular mass in peritoneal dialysis patients. Peritoneal Dialysis International, in press.
Gerstein, H.C., Alvarez, A., Bergenstal, R., Chiasson, J-L., Garrido, M., MacKinnon, I., Mohan, V., Rao, P.V., Zinman, B., Jung, H., Joldersma, L., Bosch, J., Yusuf, S. on behalf of the DREAM ON Investigators. Long-term effect of Time-limited Therapy with Rosiglitazone and/or Ramipril on the Incidence of Diabetes. Diabetologia, in press.
Anand, S.S., Dagenais, G., Mohan, V., Diaz, R., Probstfield, J., Freeman, R., Shaw, J., Marshall, S, Lanas, F, Avezum, A, Budaj, A, Jung, H., Desai, D., Bosch, J., Yusuf, S., Gerstein, H.C., on behalf of the EpiDREAM Investigators. Glucose Levels are Associated with Cardiovascular Disease and Death in an International, Middle-Aged Cohort of Normal Glycemic and Dysglycemic Men and Women: The EpiDREAM Cohort Study. European Heart Journal, submitted November, 2010.
de Koning, L., Gerstein, H.C., Bosch, J., Diaz, R., Mohan, V., Dagenais, G., Yusuf, S., & Anand, S.S. for the EpiDREAM investigators. Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. Diabetologia, epub April.
Anand, S.S., Dagenais, G., Mohan, V., Diaz, R., Probstfield, J., Freeman, R., Shaw, J., Marshall, S, Lanas, F, Avezum, A, Budaj, A, Jung, H., Desai, D., Bosch, J., Yusuf, S., Gerstein, H.C., on behalf of the EpiDREAM Investigators. Glucose Levels are Associated with Cardiovascular Disease and Death in an International, Middle-Aged Cohort of Normal Glycemic and Dysglycemic Men and Women: The EpiDREAM Cohort Study. BMJ, submitted March 11, 2010.
Lonn, E.M, Gerstein, HC, Sheridan, P, Smith, S, Diaz, R. Mohan, V, Bosch, J, Yusuf, S. (2009). Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). Journal of the American College of Cardiology, 53(22), 2028-2035.
Yusuf, S, Lonn, E, & Bosch, J. (2009). Lipid lowering for primary prevention. Lancet, 373(9670), 1152-1155.
Origin Trial Investigators. Writing Group: Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J, Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal 2008: 155(1); 26-32.
DREAM Trial Investigators. Writing Group: Dagenais GR, Gerstein HC, Holman R. Budaj A, Escalante A, Hedner T, Keltai M, Lon, E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose. Diabetes Care 2008; 31(5): 1007-1014.
Yusuf S, Bosch J, Devereaux PJ, Collins R, Baigent C, Granger C, Califf R, Temple R. Sensible guidelines for the conduct of large randomized trials. Clinical Trials 2008;5: 38-39.
Duley L, Antman K, Arena J, Avezum A, Blumenthal M, Bosch J, Chrolavicius S, Li T, Ounpuu S, Perez AC, Sleight P, Svard R, Temple R, Tsouderous Y, Yunis C, Yusuf S. Specific barriers to the conduct of randomized trials. Clin Trials 2008;5: 40-48. |